These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 25223901)

  • 21. Two anti-obesity hopefuls and their safety.
    Bello NT; Campbell SC
    Expert Opin Drug Saf; 2012 Sep; 11(5):681-3. PubMed ID: 22788876
    [No Abstract]   [Full Text] [Related]  

  • 22. Combination phentermine and topiramate for weight maintenance: the first Australian experience.
    Neoh SL; Sumithran P; Haywood CJ; Houlihan CA; Lee FT; Proietto J
    Med J Aust; 2014 Aug; 201(4):224-6. PubMed ID: 25164851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database.
    Gorelik E; Gorelik B; Masarwa R; Perlman A; Hirsh-Raccah B; Matok I
    Int J Obes (Lond); 2020 May; 44(5):1021-1027. PubMed ID: 32152496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contrave--a combination of bupropion and naltrexone for weight loss.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):112-4. PubMed ID: 25372849
    [No Abstract]   [Full Text] [Related]  

  • 25. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
    Tak YJ; Lee SY
    Curr Obes Rep; 2021 Mar; 10(1):14-30. PubMed ID: 33410104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overview of new antiobesity drugs.
    Hainer V
    Expert Opin Pharmacother; 2014 Oct; 15(14):1975-8. PubMed ID: 25100293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity.
    Bays HE; Gadde KM
    Drugs Today (Barc); 2011 Dec; 47(12):903-14. PubMed ID: 22348915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird.
    Rubio MA
    Endocrinol Nutr; 2014 Dec; 61(10):501-4. PubMed ID: 25434595
    [No Abstract]   [Full Text] [Related]  

  • 29. Antiobesity pharmacotherapy: new drugs and emerging targets.
    Kim GW; Lin JE; Blomain ES; Waldman SA
    Clin Pharmacol Ther; 2014 Jan; 95(1):53-66. PubMed ID: 24105257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topiramate + phentermine. An excessively dangerous appetite-suppressant combination.
    Prescrire Int; 2013 Mar; 22(136):61-4. PubMed ID: 23593686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Obesity Pharmacotherapy.
    Saunders KH; Umashanker D; Igel LI; Kumar RB; Aronne LJ
    Med Clin North Am; 2018 Jan; 102(1):135-148. PubMed ID: 29156182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Bello NT
    Expert Opin Drug Saf; 2019 Jul; 18(7):549-552. PubMed ID: 31092063
    [No Abstract]   [Full Text] [Related]  

  • 33. Obesity Epidemic: Pharmaceutical Weight Loss.
    Curry SA
    R I Med J (2013); 2017 Mar; 100(2):18-20. PubMed ID: 28246654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New obesity pill: new hopes, old fears.
    Lancet; 2010 Dec; 376(9758):2042. PubMed ID: 21168038
    [No Abstract]   [Full Text] [Related]  

  • 35. Phentermine and topiramate extended-release for the obesity: new kids on the block.
    Katsi V; Marketou M; Kallistratos MS; Tousoulis D; Makris T; Manolis AJ; Vardas P; Kallikazaros I
    Recent Pat Cardiovasc Drug Discov; 2013 Apr; 8(1):35-41. PubMed ID: 23565717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The risk of cardiovascular complications with current obesity drugs.
    Chao AM; Wadden TA; Berkowitz RI; Quigley K; Silvestry F
    Expert Opin Drug Saf; 2020 Sep; 19(9):1095-1104. PubMed ID: 32750250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.
    Gadde KM; Pritham Raj Y
    Curr Diab Rep; 2017 May; 17(5):34. PubMed ID: 28378293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 2 new drugs for weight loss.
    Med Lett Drugs Ther; 2012 Sep; 54(1398):69-71. PubMed ID: 22992487
    [No Abstract]   [Full Text] [Related]  

  • 39. Current and emerging pharmacotherapies for obesity in Australia.
    Hocking S; Dear A; Cowley MA
    Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
    Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
    Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.